Aberrantly-active Stat3 is detected in primary, metastatic and drug resistant tumor phenotypes and is a master regulator of events that promote cancer development and progression. Substantive work from us and others has validated that Stat3-selective inhibitors would be therapeutically useful for a variety of human cancers. Initial proof-of-concept studies from us demonstrated strong antitumor effects of the lead Stat3 inhibitors, S3I-201 and S3I-201.1066 in mouse xenografts of human breast cancer. In the present study, BP-1-102 and other BP-series of agents derived from S3I-201.1066 were characterized for their biochemical, biological and antitumor activities and found to possess strong inhibitory activities against aberrant Stat3 activity, with binding affinity (KD) of 504 nM, and IC50 values of 0.7-15 ?M. In particular, BP-1- 102 and the newly-derived agents, XW-1-053 and SH-04-54 inhibited aberrant Stat3 DNA-binding activity outside and inside cells and induced antitumor cell effects against malignant cells harboring aberrant Stat3 activity at sub-micromolar (0.7-5 ?M) activities. Initial in vivo testing showed BP-1-102 strongly inhibit growth of human breast tumors in mouse xenografts. These very promising new chemical entities are among the most potent Stat3 inhibitors identified to date. Our objective is to pursue rigorous structural analyses of the leading agents'binding to Stat3 to derive structural data that will support a hypothesis-driven intensive medicinal chemistry effort to generate agents of optimum parameters for clinical development. We hypothesize that optimized analogs would potently inhibit Stat3 activity and functions in tumor cells, possess suitable in vivo bioavailability and have high antitumor efficacy in human tumor xenografts. To achieve the Aims and the Milestones, iterative rounds of optimization through chemistry, structural analysis, biochemistry/biology, and pharmacology efforts will be performed. Data from studies of the properties of agents in Aims 1 and 2 will be fed back into chemistry to guide the optimization and the cycle repeated until suitable agents are identified, which will be tested in Aim 3 for in vivo antitumor efficacy studies using human breast cancer models in mice. Our plan thereafter is to pursue advanced, pre-clinical IND enabling studies through the NCI's RAID program or to license out the 1-2 drug candidates to a pharmaceutical company for further pre-clinical development and eventually clinical testing.

Public Health Relevance

The proposal seeks to derive clinical drug candidates from the BP-series of novel inhibitors of aberrantly-active Signal Transducer and Activator of Transcription (Stat)3, which have proven to inhibit the growth of human breast tumor xenografts in mice.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Arya, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Hawaii
Organized Research Units
United States
Zip Code
Cai, You-Sheng; Sarotti, Ariel M; G√ľndisch, Daniela et al. (2017) Heliotropiumides A and B, new phenolamides with N-carbamoyl putrescine moiety from Heliotropium foertherianum collected in Hawaii and their biological activities. Bioorg Med Chem Lett 27:4630-4634
Li, Chun-Shun; Yang, Bao-Jun; Turkson, James et al. (2017) Anti-proliferative ambuic acid derivatives from Hawaiian endophytic fungus Pestalotiopsis sp. FT172. Phytochemistry 140:77-82
Hilliard, Tyvette S; Miklossy, Gabriella; Chock, Christopher et al. (2017) 15?-methoxypuupehenol Induces Antitumor Effects In Vitro and In Vivo against Human Glioblastoma and Breast Cancer Models. Mol Cancer Ther 16:601-613
Li, Chunshun; Sarotti, Ariel M; Turkson, James et al. (2017) Verbenanone, an octahydro-5H-chromen-5-one from a Hawaiian-Plant Associated Fungus FT431. Tetrahedron Lett 58:2290-2293
Paladino, David; Yue, Peibin; Furuya, Hideki et al. (2016) A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. Oncotarget 7:7253-67
Dai, Jingqiu; Parrish, Stephen M; Yoshida, Wesley Y et al. (2016) Bromotyrosine-derived metabolites from an Indonesian marine sponge in the family Aplysinellidae (Order Verongiida). Bioorg Med Chem Lett 26:499-504
Yue, Peibin; Lopez-Tapia, Francisco; Paladino, David et al. (2016) Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. Cancer Res 76:652-63
Miklossy, Gabriella; Youn, Ui Joung; Yue, Peibin et al. (2015) Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin ?-2 Expression, and Induce Antitumor Effects against Human Glioma. J Med Chem 58:7734-48
Chelsky, Zachary L; Yue, Peibin; Kondratyuk, Tamara P et al. (2015) A Resveratrol Analogue Promotes ERKMAPK-Dependent Stat3 Serine and Tyrosine Phosphorylation Alterations and Antitumor Effects In Vitro against Human Tumor Cells. Mol Pharmacol 88:524-33
Youn, Ui Joung; Miklossy, Gabriella; Chai, Xingyun et al. (2014) Bioactive sesquiterpene lactones and other compounds isolated from Vernonia cinerea. Fitoterapia 93:194-200

Showing the most recent 10 out of 11 publications